Publications by authors named "F Koumpouras"
Article Synopsis
- Total shoulder arthroplasty (TSA) is often performed for patients with glenohumeral osteoarthritis, but comorbid conditions like systemic lupus erythematosus (SLE) can increase the risk of postoperative complications.
- In a study analyzing data from over 211,000 TSA patients, those with SLE experienced significantly higher rates of adverse events within 90 days post-surgery compared to non-SLE patients, with odds ratios indicating a notable increase in both severe and minor complications.
- Subgroup analyses revealed that SLE patients on immunomodulatory therapy had higher rates of adverse events, but there was no difference in the 5-year survival of the implants between SLE and
A defining feature of systemic lupus erythematosus (SLE) is loss of tolerance to self-DNA, and deficiency of DNASE1L3, the main enzyme responsible for chromatin degradation in blood, is also associated with SLE. This association can be found in an ultrarare population of pediatric patients with DNASE1L3 deficiency who develop SLE, adult patients with loss-of-function variants of DNASE1L3 who are at a higher risk for SLE, and patients with sporadic SLE who have neutralizing autoantibodies against DNASE1L3. To mitigate the pathogenic effects of inherited and acquired DNASE1L3 deficiencies, we engineered a long-acting enzyme biologic with dual DNASE1/DNASE1L3 activity that is resistant to DNASE1 and DNASE1L3 inhibitors.
View Article and Find Full Text PDFPurpose Of Review: Recent advances in hematology-oncology have pioneered cell-mediated elimination of pathologic B-cell populations employing chimeric antigen receptor (CAR) T cells. In this review, we discuss recent adoption of CAR-T treatment for severe refractory autoimmune disease. We highlight unique aspects of the autoimmune model and review current clinical data regarding treatment of rheumatologic disease.
View Article and Find Full Text PDFObjective: Obexelimab is an investigational, bifunctional, noncytolytic monoclonal antibody that binds CD19 and FcyRIIb to inhibit B cells, plasmablasts, and plasma cells. This trial evaluated the efficacy and safety of obexelimab in the treatment of patients with systemic lupus erythematosus (SLE).
Methods: During screening, patients with active, non-organ-threatening SLE received corticosteroid injections to ameliorate symptoms while immunosuppressants were withdrawn (≤10 mg/day prednisone equivalent and ≤400 mg/day hydroxychloroquine allowed).